Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TAS2R14 | Q9NYV8 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26114075 | 1.00 | CYP2D6 (0.58) | CYP2D6ALDH1A1KMT2AMEN1CYP2C9 | |
| SCHEMBL21987714 | 0.91 | CYP2D6 (0.52) | CYP2D6ALDH1A1KMT2AMEN1CYP2C9 | |
| SCHEMBL26350891 | 0.88 | CYP2D6 (0.58) | CYP2D6ALDH1A1KMT2AMEN1CYP2C9 | |
| SCHEMBL10376015 | 0.87 | CYP2D6 (0.67) | CYP2D6ALDH1A1KMT2ATSHRCYP1A2 | |
| SCHEMBL657896 | 0.87 | CYP2D6 (0.67) | CYP2D6ALDH1A1KMT2ATSHRCYP1A2 | |
| SCHEMBL989553 | 0.86 | CYP2D6 (0.52) | CYP2D6ALDH1A1KMT2AMEN1CYP2C9 | |
| SCHEMBL22553706 | 0.86 | CYP2D6 (0.52) | CYP2D6ALDH1A1KMT2AMEN1CYP2C9 | |
| SCHEMBL17783993 | 0.85 | ALDH1A1 (0.55) | CYP2D6ALDH1A1KMT2AMEN1CYP2C9 | |
| SCHEMBL27214135 | 0.85 | CYP2D6 (0.56) | CYP2D6ALDH1A1KMT2AMEN1CYP1A2 | |
| SCHEMBL12173630 | 0.85 | CYP2D6 (0.56) | CYP2D6ALDH1A1KMT2AMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117964623-A | Targeted protein degradation compound and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-115244053-B | Targeted protein degradation compound and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-01-30 | — | — | CN | disclosed |
| WO-2023180388-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| WO-2023069547-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023044046-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023025159-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海领泰生物医药科技有限公司 | 2023-03-02 | — | — | WO | disclosed |
| CN-115710274-A | IRAK4 degradation agent, preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2023-02-24 | — | — | CN | disclosed |
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-04 | — | — | US | disclosed |
| EP-3623372-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-03-18 | — | — | EP | disclosed |
| US-9725445-B2 | Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-08 | — | — | US | disclosed |
| CN-106459002-A | Biaryl compounds useful in the treatment of human oncological, neurological and immunological diseases | 比奥根MA公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20160280704-A1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-29 | — | — | US | disclosed |
| EP-2209790-B1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-17 | — | — | EP | disclosed |
| EP-2976340-A1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-01-27 | — | — | EP | disclosed |
| WO-2014146490-A1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-8263592-B2 | Equilibrative nucleoside transporter ENT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-11 | — | — | US | disclosed |
| US-20100280025-A1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-04 | — | — | US | disclosed |
| EP-2209790-A2 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009062990-A2 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, PYGL | CYP2D6 334/4885ALDH1A1 1615/4885KMT2A 3153/4885 |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | CYP2D6 28/4885ALDH1A1 1584/4885KMT2A 3232/4885 |
| US-20100280025-A1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | SLC29A1, SLC29A2, SLC43A3 | CYP2D6 1275/4885ALDH1A1 516/4885KMT2A 4226/4885 |
| US-20160280704-A1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | CYP2D6 632/4885ALDH1A1 1154/4885KMT2A 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.